Pharmafile Logo
Pharmafocus logo
Advanced Search

Gedeon Richter

Showing 3 posts of 3 posts found.

allergan

Allergan and Gedeon Richter’s Vraylar posts strong Phase 3 data in bipolar depression

December 19, 2017
Manufacturing and Production, Research and Development Allergan, Gedeon Richter, Vraylar, bipolar, bipolar depression, pharma

Vraylar (cariprazine), a drug developed as part of a partnership between Allergan and Gedeon Richter, has demonstrated strong results at …

News
Gedeon richter image

Gedeon Richter named and shamed

September 9, 2013
Medical Communications, Sales and Marketing ABPI, Gedeon Richter, PMCPA

Gedeon Richter (UK) has been named and shamed in advertisements by the PMCPA, which rules on breaches of the ABPI …

News

Forest depression candidate struggles against placebo

March 1, 2011
Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder

An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026